Depreciation, Depletion and Amortization of CRISPR Therapeutics AG from 31 Dec 2014 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
Summary
CRISPR Therapeutics AG annual and quarterly Depreciation, Depletion and Amortization in USD history and change rate from 31 Dec 2014 to 31 Dec 2025.
  • CRISPR Therapeutics AG Depreciation, Depletion and Amortization for the quarter ending 31 Mar 2025 was $4,736,000, a 2% decline year-over-year.
  • CRISPR Therapeutics AG annual Depreciation, Depletion and Amortization for 2025 was $19,479,000, a 1.1% increase from 2024.
  • CRISPR Therapeutics AG annual Depreciation, Depletion and Amortization for 2024 was $19,259,000, a 2.9% decline from 2023.
  • CRISPR Therapeutics AG annual Depreciation, Depletion and Amortization for 2023 was $19,837,000, a 18% decline from 2022.
Source SEC data
View on sec.gov
Depreciation, Depletion and Amortization, Annual (USD)
Depreciation, Depletion and Amortization, YoY Annual Change (%)
Depreciation, Depletion and Amortization, Quarterly (USD)
Depreciation, Depletion and Amortization, YoY Quarterly Change (%)

CRISPR Therapeutics AG Annual Depreciation, Depletion and Amortization (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $19,479,000 +$220,000 +1.1% 01 Jan 2025 31 Dec 2025 10-K 12 Feb 2026 2025 FY
2024 $19,259,000 -$578,000 -2.9% 01 Jan 2024 31 Dec 2024 10-K 12 Feb 2026 2025 FY
2023 $19,837,000 -$4,335,000 -18% 01 Jan 2023 31 Dec 2023 10-K 12 Feb 2026 2025 FY
2022 $24,172,000 +$6,219,000 +35% 01 Jan 2022 31 Dec 2022 10-K 11 Feb 2025 2024 FY
2021 $17,953,000 +$8,769,000 +95% 01 Jan 2021 31 Dec 2021 10-K 21 Feb 2024 2023 FY
2020 $9,184,000 +$4,459,000 +94% 01 Jan 2020 31 Dec 2020 10-K 21 Feb 2023 2022 FY
2019 $4,725,000 +$1,206,000 +34% 01 Jan 2019 31 Dec 2019 10-K 15 Feb 2022 2021 FY
2018 $3,519,000 +$495,000 +16% 01 Jan 2018 31 Dec 2018 10-K 16 Feb 2021 2020 FY
2017 $3,024,000 +$2,099,000 +227% 01 Jan 2017 31 Dec 2017 10-K 12 Feb 2020 2019 FY
2016 $925,000 +$798,000 +628% 01 Jan 2016 31 Dec 2016 10-K 25 Feb 2019 2018 FY
2015 $127,000 +$89,000 +234% 01 Jan 2015 31 Dec 2015 10-K 08 Mar 2018 2017 FY
2014 $38,000 01 Jan 2014 31 Dec 2014 10-K 10 Mar 2017 2016 FY

CRISPR Therapeutics AG Quarterly Depreciation, Depletion and Amortization (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $4,736,000 -$97,000 -2% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q1 2024 $4,833,000 -$218,000 -4.3% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q1 2023 $5,051,000 -$988,000 -16% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q1 2022 $6,039,000 +$3,324,000 +122% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2022 2022 Q1
Q1 2021 $2,715,000 +$624,000 +30% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q1 2020 $2,091,000 +$1,279,000 +158% 01 Jan 2020 31 Mar 2020 10-Q 27 Apr 2021 2021 Q1
Q1 2019 $812,000 -$14,000 -1.7% 01 Jan 2019 31 Mar 2019 10-Q 28 Apr 2020 2020 Q1
Q1 2018 $826,000 +$106,000 +15% 01 Jan 2018 31 Mar 2018 10-Q 29 Apr 2019 2019 Q1
Q1 2017 $720,000 +$614,000 +579% 01 Jan 2017 31 Mar 2017 10-Q 08 May 2018 2018 Q1
Q1 2016 $106,000 01 Jan 2016 31 Mar 2016 10-Q 11 May 2017 2017 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.